Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin

AIM: Sustained virologic response (SVR) can be attained with boceprevir plus peginterferon alfa and ribavirin (PR) in up to 68% of patients, and short duration therapy is possible if plasma HCV RNA levels are undetectable at treatment week 8 (TW8 response). We have developed predictive models for SV...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Alex, Devine, Scott, Kattan, Mike, Muir, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118864/
https://www.ncbi.nlm.nih.gov/pubmed/25084272
http://dx.doi.org/10.1371/journal.pone.0103370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118864/
https://www.ncbi.nlm.nih.gov/pubmed/25084272
http://dx.doi.org/10.1371/journal.pone.0103370

Ejemplares similares